Clinical Studies

Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
NeuroOphthalmology
Obesity/Weight Management
Women's Health
Other


Special Features
Advances/Research

 

Diabetes Mellitus Treatment Study using Zopolrestat
Principal Investigator:   Nicholas H.E. Mezitis, MD
Time frame of study:   Ongoing
Time frame of participation:   14 months
Number of participants needed:   Open
Location of Study:   Mount Sinai St. Luke's Roosevelt
1111 Amsterdam Avenue
Room WH1006
Contact Name, Number & Email:   Felicia Stein or Eleanor Bauza at 212-523-4171

Summary:
A multicenter, double-blind, placebo-controlled, parallel-group study of the effects of Oral Zopolrestat in Normotensive, Type 1 Diabetics with incipient Nephropathy (Microalbuminuria).

Zopolrestat is a novel medication which interferes with protein glycosylation and may delay and prevent the onset of vascular complications in diabetes mellitus.

Criteria for Participation:
Participants must be between the ages of 18 and 45 with a diagnosis of type 1 diabetes for more than 5 years. Women of child-bearing potential must be practicing a medically-approved method of birth control.

Benefits and/or Compensation:
Persons who qualify will receive free physical examinations, laboratory tests, electrocardiograms, kidney function tests, a blood glucose meter and supplies, medical supervision and a stipend.